- Page 1 and 2: Driven by the future Growth, Compet
- Page 3 and 4: Highlights January 2005 Solvay fi n
- Page 5 and 6: Activities Group sales 2005 = EUR 8
- Page 7 and 8: Our Vision - Independent industrial
- Page 9 and 10: here to stay, in our view irreversi
- Page 11: Board of Directors and Corporate Go
- Page 15 and 16: Such a strategy is possible only wi
- Page 17 and 18: Specialities Solvay Specialties fro
- Page 19 and 20: Key fi gures [EUR million] Pharmace
- Page 21 and 22: Cardiometabolic Cardiovascular dise
- Page 23 and 24: Cardiometabolics Fenofi brate, TRIC
- Page 25 and 26: “ DUODOPA® entered Solvay’s pr
- Page 27 and 28: Pharmaceuticals Sector Therapeutic
- Page 29 and 30: Key fi gures [EUR million] Chemical
- Page 31 and 32: Growth To speed up its growth, the
- Page 33 and 34: Initiatives have also been launched
- Page 35 and 36: “ The ‘Soil Remediation Reagent
- Page 37 and 38: Key fi gures [EUR million] Plastics
- Page 39 and 40: Innovation “Twin-Sheet Blow Mould
- Page 41 and 42: Plastics 37 Solvay Global Annual Re
- Page 43 and 44: which it was able to take advantage
- Page 45 and 46: New Business Development Priority t
- Page 47 and 48: Meeting The Science Days organized
- Page 49 and 50: Human Resources The Group’s fi ve
- Page 51 and 52: “ At the end of this seminar, all
- Page 53 and 54: Sustainable Development 2005 saw th
- Page 55 and 56: Accident frequency rate Persons wor
- Page 57 and 58: Management Report New records for S
- Page 59 and 60: Expenditure on the future by Sector
- Page 61 and 62: Financial Statements The following
- Page 63 and 64:
Consolidated balance sheet EUR mill
- Page 65 and 66:
IFRS valuation rules The main accou
- Page 67 and 68:
9. Impairment Every year the Group
- Page 69 and 70:
Notes to the fi nancial statements
- Page 71 and 72:
(2) Financial data by region These
- Page 73 and 74:
and the estimated fi nancial conseq
- Page 75 and 76:
The deferred taxes recorded in the
- Page 77 and 78:
2005 Millions EUR Acquisitions Disp
- Page 79 and 80:
Neopharma On January 19, 2005 the S
- Page 81 and 82:
(around 300 persons) with a view to
- Page 83 and 84:
In 2005 the impairment tests on goo
- Page 85 and 86:
Solvay Group purchased 100% of the
- Page 87 and 88:
Post-employment benefi t plans are
- Page 89 and 90:
Actuarial assumptions used in deter
- Page 91 and 92:
Analysis of total fi nancial debt b
- Page 93 and 94:
In this way, at the end of 2005, th
- Page 95 and 96:
The following amounts relating to J
- Page 97 and 98:
PORTUGAL Fournier Farmaceutica Port
- Page 99 and 100:
List of fully consolidated Group co
- Page 101 and 102:
Solvay Salz Holding GmbH, Hannover
- Page 103 and 104:
CANADA Fournier Pharma, Inc., Montr
- Page 105 and 106:
GREAT BRITAIN Inergy Automotive Sys
- Page 107 and 108:
Summary fi nancial statements of So
- Page 109 and 110:
Statutory auditor’s report to the
- Page 111 and 112:
The Solvay share compared with the
- Page 113 and 114:
Contacts: The Investor Relations Te
- Page 115 and 116:
Shareholders’ Diary - May 9, 2006